Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Operating Leases (2019 - 2025)

Historic Operating Leases for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $10.5 million.

  • aTYR PHARMA's Operating Leases fell 705.15% to $10.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.5 million, marking a year-over-year decrease of 705.15%. This contributed to the annual value of $11.1 million for FY2024, which is 968.47% down from last year.
  • aTYR PHARMA's Operating Leases amounted to $10.5 million in Q3 2025, which was down 705.15% from $10.7 million recorded in Q2 2025.
  • In the past 5 years, aTYR PHARMA's Operating Leases registered a high of $12.8 million during Q2 2023, and its lowest value of $133000.0 during Q1 2022.
  • Moreover, its 5-year median value for Operating Leases was $10.8 million (2025), whereas its average is $8.2 million.
  • In the last 5 years, aTYR PHARMA's Operating Leases tumbled by 8838.43% in 2022 and then skyrocketed by 885939.85% in 2023.
  • Over the past 5 years, aTYR PHARMA's Operating Leases (Quarter) stood at $398000.0 in 2021, then soared by 2320.35% to $9.6 million in 2022, then grew by 28.09% to $12.3 million in 2023, then decreased by 9.68% to $11.1 million in 2024, then decreased by 5.49% to $10.5 million in 2025.
  • Its Operating Leases stands at $10.5 million for Q3 2025, versus $10.7 million for Q2 2025 and $11.0 million for Q1 2025.